mofetil and two (9.5%) with tacrolimus. Treatment schemes: eight (38.1%) patients received 15 day cycles with a fixed dose of 1000 mg on days 1 and 15. Ten patients (47.6%) with 500 mg weekly for 4 weeks and three patients (14.3%) received doses of 875 mg/m² weekly for 4 weeks. Adverse reactions: 11 patients (52.4%) developed cytopenia. The most frequent cytopenia was anaemia: five patients 45.4%. Seven (33.3%) patients developed pneumonia or sepsis that required hospital admission. A case of atrial fibrillation was recorded. No reactions related to the perfusion of rituximab were recorded.

Conclusion The use of rituximab off-label has increased in recent years. It is therefore necessary to develop protocols to unify the criteria for use, evaluating its effectiveness and safety profile to increase the quality of care.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Background Hospital pharmacovigilance (PV) has always shown an irregular trend. High increases in the use of adverse drug reactions (ADR) reporting are often recorded during the times in which ad hoc surveillance projects are also carried out. There are several reasons: the lack of knowledge about the role of the PV, the underestimation of the iatrogenic illnesses, job organisation problems and the perception of PV as a merely bureaucratic procedure.

Purpose The purpose of the survey was to suggest the use of some practical and quick tools that could help the staff of the hospital reporting the ADRs in a continuous and spontaneous way, without interfering in the ordinary management of the patients.

Material and methods The entire hospital staff was asked to take part in a survey sent by company e-mail. The survey consisted of 15 questions, which the participants could answer online anonymously. The first part of the questionnaire concerned the meaning of ADR, while the second one examined useful tools for the encouragement of the surveillance. The results were analysed through Microsoft Excel and LimeSurvey.

Results Two-thousand, six-hundred and seventy-two surveys were included. Thirteen studies were performed in a hospital setting, whereas the rest were population-based studies and the rest used mixed populations. Follow-up periods differed from length of hospital stay to 10 years. Eighteen of 34 studies found a significant association between the anticholinergic burden of medications and mortality in older adults. It has demonstrated a negative impact on health outcomes such as cognitive impairment or falls, and many studies have recently investigated the association with a higher risk of mortality, but findings are contradictory.

Purpose To summarise with a systematic review of the evidence regarding the association between the anticholinergic burden of medications and mortality in older adults.

Material and methods A scientific literature search was conducted to identify all relevant studies published from 2006 until May 2018, without applying language restrictions. Queries of the literature were performed using the electronic databases PubMed (MEDLINE), EMBASE, Web of Science, CENTRAL and PsycINFO. A combination of the search terms used was: ‘aged’ AND ‘anticholinergic’ AND ‘mortality’. Studies with any type of design and setting with participants of mean age 65 years or older were included.

Results Two-thousand and twenty-eight different studies were identified, and after a two-step review, 34 were finally included in the systematic review (total 1,142,613 participants, from 71 to 537,387). All of them were observational studies: one case-control study and 33 cohort studies (nine retrospective and 24 prospective). Fourteen different scales were used: Anticholinergic Risk Scale, Drug Burden Index and Anti-Cholinergic Burden Scale were the most commonly used. Thirty studies were performed in a hospital setting, seven in nursing homes, seven in a community dwelling, four were population-based studies and the rest used mixed populations. Follow-up periods differed from length of hospital stay to 10 years. Eighteen of 34 studies found a significant association between the anticholinergic burden of medications and an increased risk of mortality, in different settings and wards in the comprehension of the reporting procedures is considered rather important.

Furthermore, it is recommended to add a checkbox for the ADRs in the software for the patients’ management to promote the use of such an activity in the long term. In addition, the QPPV should have access to medical reports and useful data so that thorough and high-standard ADR reports could be provided.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.
with different anticholinergic scales (six of 13 studies with hospitalised patients).

**Conclusion** A high anticholinergic burden may increase the risk of mortality in older adults, but further well-designed research is needed to confirm this finding. A reduction of anticholinergic burden could be a cautious strategy to reduce the risk of mortality and other adverse outcomes. Hospital is a suitable setting to perform medication reviews in older adults to reduce this risk and clinical pharmacists can play an important role for this purpose.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**PSQ-134**  
**ANALYSIS OF MEDICATION DISCREPANCIES AS PART OF THE CLINICAL PHARMACY MEDICATION RECONCILIATION PROCESS**

1,2L Hayes*, 1A Harnett, 1L Sahm. 1University Hospital Limerick, Pharmacy, Limerick, Ireland; 2University College Cork, Pharmacy, Cork, Ireland

10.1136/ejhp-2019-eahpconf.567

**Background** It is widely accepted that the transition of patients across organisations or between professionals is a vulnerable time with regards to medication safety. Approximately 20% of all adverse drug events (ADE) are attributed to poor communication at transitions of care. Completing a medication reconciliation or MedRec for patients at these junctures may be an important means for improving medication safety, and studies have identified that clinical pharmacists contribute positively to MedRec on admission to hospital.

**Purpose** The study aimed to assess the impact of clinical pharmacy-led MedRec, within the adult patient population upon admission to an acute hospital.

**Material and methods** This observational, prospective study took place over a 4 week period in March 2018 in an urban, acute, university-affiliated teaching hospital. Data were collected on 205 patients as a part of the normal delivery of services. When MedRec was completed for a patient, the number of apparently unintentional discrepancies were recorded. At 24 and 48 hours, the number of unintentional discrepancies (UD), intentional discrepancies, unresolved discrepancies and the details of the discrepancies were recorded. An expert review panel rated the discrepancies using the numerical rating score according to the potential for harm to the patient if the CP had not intervened.

**Results** Almost two-thirds of patients (n=205) experienced a CP intervention or endorsement regarding apparently UD. Unintentional discrepancies affected 51% of patients and were associated with 17% of medications reviewed (n=1384). There was a statistically significant positive association between the number of pre-admission medications a patient was taking and UD (r=0.26, p<0.0001). Almost 90% of UD were reported as having the potential to cause moderate harm to the patient: 2.5% were considered to potentially cause serious harm.

**Conclusion** Pharmacy-led MedRec has a positive effect on patient safety at transitions of care. Longitudinal research is needed to examine the clinical effect that discrepancies have on patient outcomes.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

n/a.

No conflict of interest.